達諾生技株式会社
深海高純度魚油保健食品 | 達諾生技股份有限公司

FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups (December 13, 2019)

日付:2020-05-04

から引用された記事:https://bit.ly/2X5Qlws

 
The U.S. Food and Drug Administration today approved the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
TOP